The innovator brand for cefuroxime is Zinacef [1]. Cefuroxime is a cephalosporin antibiotic [1].
When does Zinacef's patent expire?
Information regarding the specific patent expiry dates for Zinacef is not readily available in the provided text. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods [2].
What is Zinacef used to treat?
Zinacef, or cefuroxime, is used to treat a variety of bacterial infections [1]. These can include respiratory tract infections, urinary tract infections, skin and soft tissue infections, and gynecological infections [1]. It is also used in the prevention of infections following surgery [1].
How does Zinacef work?
Cefuroxime is a bactericidal antibiotic, meaning it kills bacteria [1]. It works by inhibiting the synthesis of the bacterial cell wall, which is essential for bacterial survival [1]. This mechanism of action makes it effective against a range of Gram-positive and Gram-negative bacteria [1].
Are there generic versions of Zinacef available?
Yes, generic versions of cefuroxime are available [1]. The availability of generics indicates that the patent protection for the innovator drug has expired or is no longer in effect, allowing other companies to produce and market the medication [3].
Who manufactures Zinacef?
GlaxoSmithKline (GSK) is the manufacturer of the innovator brand Zinacef [1].
What are the side effects of Cefuroxime?
Common side effects associated with cefuroxime include nausea, vomiting, diarrhea, and headache [1]. More serious, though less common, side effects can include allergic reactions, liver problems, and changes in blood cell counts [1].
How is Cefuroxime administered?
Cefuroxime can be administered intravenously (IV), intramuscularly (IM), or orally, depending on the specific formulation and the type of infection being treated [1].
What is the difference between Cefuroxime and other cephalosporins?
Cefuroxime belongs to the second generation of cephalosporin antibiotics [1]. Second-generation cephalosporins generally have a broader spectrum of activity than first-generation drugs, particularly against Gram-negative bacteria, while retaining good activity against Gram-positive organisms [1]. They also have increased resistance to beta-lactamases, enzymes produced by bacteria that can inactivate antibiotics [1].
What clinical trials have been conducted for Cefuroxime?
Clinical trials have evaluated cefuroxime's efficacy and safety across various infections and patient populations [1]. These trials contribute to understanding its effectiveness in treating conditions like pneumonia, sinusitis, and urinary tract infections, as well as its role in surgical prophylaxis [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/cefuroxime
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/about-drug-patents